semaglutide essence trial (#wegovy/#ozempic) has better results, thus far, in its phase 3 fatty liver than its previous phase 2 trial it seems. 72-week data presented at The Liver Meeting 2024: American Association Metabolic dysfunction-associated steatotic liver disease
Description
De officile bijsluiter van dit medicijn vindt u bij het College ter Beoordeling van Geneesmiddelen op: www.cbg-meb.nl.
Semaglutide nausea is a common adverse effect
10.1056/NEJMoa1411892 98
The Data Gap: From Information Anxiety to Proactive Care Its exhausting when a test result arrives, and you are the only person connecting the dots between a new medication dose, a skipped protein goal, or a stormy night of dehydration
Terrific for appetite control, less terrific for digestive calm
Its even better than its more widely available cousin, semaglutide, as shown by several large-scale studies
